#Singapore #Immunotherapy #gynaecological cancer #clear cell carcinoma

Dual-Pathway Blockade Therapy: A New Hope for Rare Gynaecological Cancers

In recent years, advancements in medical research have led to innovative treatment approaches for various cancer types. Among these, a dual-pathway blockade therapy involving a combination of pembrolizumab and lenvatinib is paving the way for treating rare and difficult-to-manage gynaecological clear cell cancers. This breakthrough has been highlighted following a promising clinical trial involving patients suffering from these challenging forms of cancer.

Background of the Patients

Before her cancer diagnosis in early 2017, Caitlin Delaney, a 48-year-old resident of Australia, experienced severe fatigue, chronic sinusitis, and significant changes in her appetite, specifically an aversion to chocolate and alcohol. Comprehensive testing led to a staggering discovery: advanced clear cell ovarian cancer.

Similarly, Michelle, another patient aged 49, found her way to diagnosis later in 2022 after months of intense acid reflux, bloating, and persistent indigestion. Both women underwent standard treatments, including surgery and chemotherapy, which unfortunately led to recurrent cancers and metastasis.

Innovative Treatment Approach

Caitlin's treatment journey took a pivotal turn when she was introduced to the dual-pathway therapy on the recommendation of Associate Professor David Tan from the National University Cancer Institute, Singapore (NCIS). Meanwhile, Michelle participated in a new international clinical trial led by Assoc Prof Tan, known as the LARA trial. This trial is part of a larger initiative supported by the Asia Pacific Gynecologic Oncology Trials Group (APGOT), aimed at filling the treatment gap for clear cell cancers.

The significance of the LARA trial lies in its position as the first Asia-led multicenter initiative to exhibit promising outcomes for patients who previously experienced resistance to conventional therapies. While similar treatments have been explored globally, this trial stands out, thanks to the rigorous collaboration between research institutions across Singapore and South Korea.

Trial Results and Findings

Published in The Lancet Oncology, the LARA trial investigated the effectiveness of combining pembrolizumab, an immunotherapy agent, and lenvatinib, a targeted therapy. This combination was shown to boost the immune response while also blocking signals that aid tumor growth and blood vessel formation. The results were significant: 40% of participants demonstrated confirmed tumor responses, achieving a measure of shrinkage by over 30% within 24 weeks of treatment. Furthermore, the median progression-free survival rate was reported at 6.4 months, providing a glimmer of hope for patients in dire need of effective therapy options.

Throughout the trial, side effects were noted to be manageable, with no reported treatment-related deaths.

Importance of Continued Research

The results from the LARA trial mark a critical development, especially in regions like Singapore, where clear cell cancers account for approximately 30% of ovarian cancer cases. Assoc Prof Tan emphasized the importance of continuing this research to maintain momentum for developing effective treatments in this clinically aggressive cancer subtype. Additionally, he cited a related US study that corroborated the LARA trial's findings, underscoring the validity and importance of this new therapeutic strategy.

Both Caitlin and Michelle's experiences embody the potential of this novel treatment to improve disease control and enhance quality of life despite the persistent challenge of cancer. Caitlin described the nearly two and a half years on the therapy as her most stable and fulfilling period, allowing her to engage in social activities and advocate for fellow patients.

Dr. Natalie Ngoi from NCIS, who authored the study, echoed the necessity to recognize the courage of patients who participate in such trials. She pointed out that their involvement is vital for advancing treatments in rare cancer subtypes that are often overlooked in larger randomized trials.

Conclusion

The findings from this groundbreaking LARA trial introduce a much-needed pathway for patients suffering from rare gynaecological clear cell cancers, promising renewed hope for better outcomes. As ongoing studies take shape, there's a collective hope that dual-pathway therapies such as this will soon be more widely available, advancing the treatment landscape for these challenging and often under-represented cancers.

This research, supported by the Singapore Ministry of Health, highlights the vital role of government initiatives and philanthropic contributions in propelling cancer research forward, ultimately aiming to provide patients with a broader spectrum of therapeutic options.